Abstract: Clinical Infectious Diseases Major Article Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States Michael W. Fried,1 Julie M. Crawford,1 Andrea R. Mospan,1 Stephanie E. Watkins,1 Breda Munoz,1 Richard C. Zink,1 Sherry Elliott,2 Kyle Burleson,1 Charles Landis,3 K. Rajender Reddy,4 and Robert S. Brown Jr5 Background. As coronavirus disease 2019 (COVID-19) disseminates throughout the United States, a better understanding of the patient characteristics associated with hospitalization, morbidity, and mortality in diverse geographic regions is essential. Methods. Hospital chargemaster data on adult patients with COVID-19 admitted to 245 hospitals across 38 states between 15 February and 20 April 2020 were assessed. The clinical course from admission, through hospitalization, and to discharge or death was analyzed. Results. A total of 11 721 patients were included (majority were >60 years of age [59.9%] and male [53.4%]). Comorbidities included hypertension (46.7%), diabetes (27.8%), cardiovascular disease (18.6%), obesity (16.1%), and chronic kidney disease (12.2%). Mechanical ventilation was required by 1967 patients (16.8%). Mortality among hospitalized patients was 21.4% and increased to 70.5% among those on mechanical ventilation. Male sex, older age, obesity, geographic region, and the presence of chronic kidney disease or a preexisting cardiovascular disease were associated with increased odds of mechanical ventilation. All aforementioned risk factors, with the exception of obesity, were associated with increased odds of death (all P values < .001). Many patients received investigational medications for treatment of COVID-19, including 48 patients on remdesivir and 4232 on hydroxychloroquine. Conclusions. This large observational cohort describes the clinical course and identifies factors associated with the outcomes of hospitalized patients with COVID-19 across the United States. These data can inform strategies to prioritize prevention and treatment for this disease. Keywords. SARS-CoV-2; COVID-19; observational study; hydroxychloroquine; remdesivir. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] is a novel coronavirus identified initially in Wuhan, China, in 2019. The virus causes coronavirus disease 2019 (COVID-19) [2], which subsequently has created outbreaks across the world, resulting in over 5.2 million cases and over 327 000 deaths globally [3]. In the United States, the first case of COVID-19 was reported on 20 January 2020 in Washington state [4]. As of 5 August 2020, there have been over 4.6 million confirmed cases and 154 952 deaths attributed to COVID-19 in the United States [3]. In early reports in China and the United States, increasing age and comorbid diseases, most notably cardiovascular disease, diabetes, hypertension, and chronic kidney disease, were associated with increased disease severity and death [5–7]. According to the Centers for Disease Control and Prevention Received 5 June 2020; editorial decision 19 August 2020; accepted 24 August 2020; published online August 28, 2020. Correspondence: M. W. Fried, TARGET PharmaSolutions, Inc., 2520 Meridian Pkwy, Suite 105, Durham, NC 27713 (mfried@targetpharmasolutions.com). Clinical Infectious Diseases®  2021;72(10):e558–65 © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions,..